Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Neurocrine Biosciences initiated a Phase 2 study of NBI-'567, an oral M1/M4-preferring muscarinic agonist, as adjunctive treatment for cognitive impairment in mild to moderate Alzheimer's disease. The randomized, double-blind, placebo-controlled trial will enroll approximately 135 adults ages 50-85 on stable acetylcholinesterase inhibitor therapy, with a 12-week treatment period and a primary endpoint of change in a Neuropsychological Test Battery composite score at Week 12.
Key figures
- Drug Name
- NBI-'567 (NBI-1117567)
- Phase Of Trial
- Phase 2
- Enrollment
- 135
- Primary endpoint
- Change from baseline in Neuropsychological Test Battery composite score at Week 12
- Treatment duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.